Discovery of novel microsomal prostaglandin E2 synthase 1 (mPGES-1) inhibitors by a structurally inspired virtual screening study

被引:0
|
作者
Olgac, Abdurrahman [1 ,2 ]
Jordan, Paul M. [3 ]
Kretzer, Christian [3 ]
Werz, Oliver [3 ]
Banoglu, Erden [1 ]
机构
[1] Gazi Univ, Fac Pharm, Dept Pharmaceut Chem, TR-06560 Ankara, Turkiye
[2] Evias Pharmaceut R&D Ltd, Dept Drug Discovery, Gazi Teknopk, TR-06830 Ankara, Turkiye
[3] Friedrich Schiller Univ Jena, Dept Pharmaceut Med Chem, D-07743 Jena, Germany
关键词
Prostaglandin; mPGES-1; Cyclooxygenase; Arachidonic acid; Docking; Virtual screening; E-2; SYNTHASE-1; ACCURATE DOCKING; IDENTIFICATION; POTENT; INTERFERENCE; PROTEINS; DESIGN; GLIDE;
D O I
10.1016/j.jmgm.2025.108962
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Prostaglandin (PG) E2 is a pro-inflammatory lipid mediator derived from the metabolism of arachidonic acid (AA) by cyclooxygenases (COX) and PGE2 synthases. Nonsteroidal anti-inflammatory drugs (NSAIDs), commonly used in the treatment of inflammation, nonselectively inhibit COX activity and decrease PGE2 production. However, these drugs cause gastrointestinal bleeding and several cardiovascular complications. Therefore, inhibiting microsomal PGE2 Synthase-1 (mPGES-1) to block PGE2 production downstream of COX is expected to yield safer and more effective treatments for inflammation, cancer, and cardiovascular diseases. At present, there are no mPGES-1 inhibitors available on the market, but ongoing research continuously evaluates new compounds in both preclinical and clinical stages. Here, we conducted a high throughput virtual screening campaign to discover novel mPGES-1 inhibitor scaffolds. This campaign utilized physicochemical filtering alongside both structure-aware ligand-based approaches (shape screening templates and pharmacophore models, which were generated based on the 3D binding modes of the co-crystallized mPGES-1 inhibitors) and structure-based strategies (refinement with docking and molecular dynamics). Thirty-four compounds were selected and biologically tested for mPGES-1 inhibition in a cell-free assay using microsomes from interleukin-1 beta-stimulated A549 cells as the source of mPGES-1. The most potent compound inhibited the remaining enzyme activity with an IC50 value of 6.46 mu M in a cell-free assay for PGE2 production. We also compared the binding patterns of the most active compounds identified in this study with those of co-crystallized inhibitors using molecular dynamics simulations. This comparison underscored the crucial role of ionic interactions, it-it interactions, hydrogen bonds, and water bridges involving specific amino acids. Our results highlight the importance of these interaction networks within the binding cavity in various binding scenarios. Ultimately, the insights gained from this study could assist in designing and developing new mPGES-1 inhibitors.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1
    Wu, Tom Y. H.
    Juteau, Helene
    Ducharme, Yves
    Friesen, Richard W.
    Guiral, Sebastien
    Dufresne, Lynn
    Poirier, Hugo
    Salem, Myriam
    Riendeau, Denis
    Mancini, Joseph
    Brideau, Christine
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (23) : 6978 - 6982
  • [32] INHIBITION OF MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES-1) BY GS-248 REDUCES PROSTAGLANDIN E2 BIOSYNTHESIS WHILE INCREASING PROSTACYCLIN IN HUMAN SUBJECTS
    Edenius, C.
    Ekstrom, G.
    Kolmert, J.
    Morgenstern, R.
    Stenberg, P.
    Jakobsson, P. J.
    Tornling, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1099 - 1099
  • [33] The inducible prostaglandin E synthase (mPGES-1) in neuroinflammatory disorders
    Sluter, Madison N.
    Li, Qianqian
    Yasmen, Nelufar
    Chen, Yu
    Li, Lexiao
    Hou, Ruida
    Yu, Ying
    Yang, Chao-Yie
    Meibohm, Bernd
    Jiang, Jianxiong
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2023, 248 (09) : 811 - 819
  • [34] Regulation of microsomal prostaglandin E synthase-1 (mPGES-1) expression in activated primary rat microglia
    Oliveira, A. C. P.
    Candelario-Jalil, E.
    Bhatia, H. S.
    Huell, M.
    Fiebich, B. L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S32 - S33
  • [35] Computer-Aided Drug Design of Anti-inflammatory Agents Targeting Microsomal Prostaglandin E2 Synthase-1 (mPGES-1)
    dos Santos Nascimento, Igor Jose
    de Aquino, Thiago Mendonca
    da Silva Junior, Edeildo Ferreira
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (33) : 5397 - 5419
  • [36] Microsomal prostaglandin E synthase-1 (mPGES-1) prevents Fas-induced liver injury
    Yao, Lu
    Han, Chang
    Wu, Tong
    HEPATOLOGY, 2014, 60 : 720A - 720A
  • [37] Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase
    Ergul, Azize Gizem
    Maz, Tugce Gur
    Kretzer, Christian
    Olgac, Abdurrahman
    Jordan, Paul M.
    Caliskan, Burcu
    Werz, Oliver
    Banoglu, Erden
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 231
  • [38] Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review
    Psarra, Anastasia
    Nikolaou, Aikaterini
    Kokotou, Maroula G.
    Limnios, Dimitris
    Kokotos, George
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2017, 27 (09) : 1047 - 1059
  • [39] Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2
    Annaleise V Sampey
    Seetha Monrad
    Leslie J Crofford
    Arthritis Research & Therapy, 7
  • [40] Microsomal prostaglandin E synthase-1:: the inducible synthase for prostaglandin E2
    Sampey, AV
    Monrad, S
    Crofford, LJ
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (03) : 114 - 117